Navigation Links
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

ISELIN, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Daylight Time). The conference is taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

In the presentation, Mr. Neill will provide an update on the Company's business and product pipeline. A webcast of the presentation will be available and archived for 90 days after the conference at http://www.wsw.com/webcast/rrshq13/pars. For additional information on this conference please visit http://www.rodmanandrenshaw.com/conferences?id=18.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with IBS. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthr
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... Nov. 19 Arete Therapeutics Inc., ... first-in-class soluble epoxide,hydrolase (s-EH) ... final,tranche of its Series A financing. Frazier... $16.7 million tranche, which also included existi...rtners, and Altitude Life Science,Ventures. This...
(Date:11/18/2008)...- Friction is the bane of any machine. When movin...rgy to move them, the machine doesn,t operate as e...out over time. , But if you could manufacture p...be less friction, requiring less input energy and ....S. Department of Energy,s (DOE) Ames Laboratory a...
(Date:11/18/2008)...China, Nov. 18 ,Benda Ph...hina-based,pharmaceutical company producing both ...ine for the treatment of cancer, and traditional C...d financial results for the three and,nine month ...ends to file its,Form 10-Q with the SEC today. ,...
(Date:11/18/2008)... StollerUSA, the world leader in developm...genetic expression, has utilized the latest in Web..., www.StollerUSA.com . Highlights of the updated ...rch, farmer interviews and a blogging forum where ...s. , Houston, Texas (PRWE...
Breaking Biology Technology:Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 2Nanocoatings boost industrial energy efficiency 2Nanocoatings boost industrial energy efficiency 3Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 2Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 3Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 4Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 5Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 6Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 7Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 8Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 9StollerUSA Launches Updated Web site For Growers and Farmers 2
... AT&T expands retail distribution of Internet te... Superconnect software TeraMedica hires new VP ...orce lab Engineers manipulate single electrons ...jumps on earthquake study opportunity AT&T ex...rvice , AT&T has announced that it will add Cir...
... Shereshewsky, right, receives an award from Raj ... Madison, Wis. Marketing in a digital universe i...reshewsky, ambassador plenipotentiary to Madison A...dent (and cohort of former Madison Mayor Paul Sogl...e his impact on the future of business. He was a R...
... Conjugons offices are located in the MG&E Innova..., Wis. Medical research group ConjuGon announc...an investment of $1.1 million dollars from angel i... Partners . The new funds will be directed to the ... testing of biotheraputic treatments. , ,ConjuGon ...
... UW-Extension gets $95,000 to help small busines...aller hospitals Single gene could make deadly d...Ink Source now property of Nor-Cote UW students...o track trucks SunTrust to implement Fiserv,s E...elp small businesses ,The University of Wisconsin...
Other Biology Technology:Tech Digest: what's moving in the Midwest 2Tech Digest: what's moving in the Midwest 3Advertising ambassador explains the reinvention of marketing 2Advertising ambassador explains the reinvention of marketing 3ConjuGon lands $1 million angel investment 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:11/18/2008)...swire-FirstCall/ -- Orchid Cellmark Inc.,(Nasdaq:...y DNA testing services,today reported its financ... Total revenues were $14.9 million for the third ... third quarter of 2007. The decrease in total,re... year ago was largely due,to lower revenues in th...
(Date:11/18/2008)...ists says that the level of globe-warming carbon d...oint where world climate will change disastrously ... The study is a departure from recent estimates th...ter in this century. The paper appears in the cur...nal . , "There is a bright side to this conclusi...
(Date:11/18/2008)...08 -- Researchers at the University of California,...r drugs have been used to block and reverse type 1...d in The Proceedings of the National Academy of S...ector of the Diabetes Center at UCSF and an expert...uggest that kinase inhibitors successfully used i...
(Date:11/18/2008)...8 A team led by a Texas A&M University anthropolo...live in 85 years. The pygmy tarsiers, furry Furby/...ll mouse and weighing less than 2 ounces, have not...a museum in 1921. Several scientists believed they...ping rats in the highlands of Sulawesi accidentall...
Breaking Biology News(10 mins):Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Carbon dioxide already in danger zone, warns study 2Texas A&M anthropologist discovers long-lost primate in Indonesia 2DIA FDA PhRMA Drug Safety Conference 3A Planning the Lifecycle of Safety Evaluation 26678 1DIA FDA PhRMA Drug Safety Conference 3A Planning the Lifecycle of Safety Evaluation 26678 2New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 1New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 2American Beverage Association Statement on Caffeinated Energy Drinks 26674 1American Beverage Association Statement on Caffeinated Energy Drinks 26674 2Promptu Unveils High Accuracy Voice to Text Dictation for Mobile Phones at CTIA 5041 1Promptu Unveils High Accuracy Voice to Text Dictation for Mobile Phones at CTIA 5041 2
...r to understanding how breast cancer spreads to ot...d this week. , The University of Manchester team h...e spread or "metastatic progression" of tumors. ,... to new approaches to treating breast cancer as bl...stop cancerous cells migrating. , "What we have i...
...lography obtaining a three-dimensional model of a ...ars of tedious calculations by hand. Today macromo...ophisticated software and in particular a package ... Hamburg Outstation of the European Molecular Biol...he Netherlands Cancer Institute (NKI) in Amsterdam...
...his, Tennessee for the Ecological Society of Ameri...in the state will be presenting the results of the...highlights: , Past and present declines in Hemloc...ional Park Monday August 7, 5 ?6:30 PM, Exhibit Ha...Adelgid (HWA) (Adelges tsugae) has brought about d...
...olecule that inhibits proliferation of a broad ran...n vivo. The findings, published in the May issue o...ly members are most likely to play a role in cance...hat successful small molecule kinase inhibitors mu...uate the complex signaling pathways involved in ma...
Other Biology News:Research links protein to breast-cancer migration 2Mapping the protein world 2Ecosystem services and invasive species 2Ecosystem services and invasive species 3Unique dual target specificity of kinase inhibitor key for success against cancer 2
Prepared in distilled water.
The RiboGreen RNA Quantitation Kit is one of the most sensitive detection systems for the quantitation of RNA in solution. The assay is approximately 1000-fold more sensitive than absorbance measure
Request Info
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)
Biology Products: